S&P 500   5,144.36 (-1.05%)
DOW   38,129.72 (-0.86%)
QQQ   440.35 (-1.13%)
AAPL   176.07 (+0.59%)
MSFT   424.12 (-0.89%)
META   516.58 (-1.26%)
GOOGL   158.62 (-0.50%)
AMZN   187.40 (-0.87%)
TSLA   172.48 (-1.21%)
NVDA   893.65 (-1.38%)
AMD   163.99 (-3.82%)
NIO   4.14 (-7.17%)
BABA   72.37 (-3.31%)
T   16.43 (+0.06%)
F   12.70 (-2.61%)
MU   123.52 (-3.13%)
GE   155.08 (-1.47%)
CGC   8.01 (-1.72%)
DIS   114.51 (-2.25%)
AMC   2.71 (-3.21%)
PFE   26.19 (-0.57%)
PYPL   65.25 (-0.84%)
XOM   122.28 (+0.40%)
S&P 500   5,144.36 (-1.05%)
DOW   38,129.72 (-0.86%)
QQQ   440.35 (-1.13%)
AAPL   176.07 (+0.59%)
MSFT   424.12 (-0.89%)
META   516.58 (-1.26%)
GOOGL   158.62 (-0.50%)
AMZN   187.40 (-0.87%)
TSLA   172.48 (-1.21%)
NVDA   893.65 (-1.38%)
AMD   163.99 (-3.82%)
NIO   4.14 (-7.17%)
BABA   72.37 (-3.31%)
T   16.43 (+0.06%)
F   12.70 (-2.61%)
MU   123.52 (-3.13%)
GE   155.08 (-1.47%)
CGC   8.01 (-1.72%)
DIS   114.51 (-2.25%)
AMC   2.71 (-3.21%)
PFE   26.19 (-0.57%)
PYPL   65.25 (-0.84%)
XOM   122.28 (+0.40%)
S&P 500   5,144.36 (-1.05%)
DOW   38,129.72 (-0.86%)
QQQ   440.35 (-1.13%)
AAPL   176.07 (+0.59%)
MSFT   424.12 (-0.89%)
META   516.58 (-1.26%)
GOOGL   158.62 (-0.50%)
AMZN   187.40 (-0.87%)
TSLA   172.48 (-1.21%)
NVDA   893.65 (-1.38%)
AMD   163.99 (-3.82%)
NIO   4.14 (-7.17%)
BABA   72.37 (-3.31%)
T   16.43 (+0.06%)
F   12.70 (-2.61%)
MU   123.52 (-3.13%)
GE   155.08 (-1.47%)
CGC   8.01 (-1.72%)
DIS   114.51 (-2.25%)
AMC   2.71 (-3.21%)
PFE   26.19 (-0.57%)
PYPL   65.25 (-0.84%)
XOM   122.28 (+0.40%)
S&P 500   5,144.36 (-1.05%)
DOW   38,129.72 (-0.86%)
QQQ   440.35 (-1.13%)
AAPL   176.07 (+0.59%)
MSFT   424.12 (-0.89%)
META   516.58 (-1.26%)
GOOGL   158.62 (-0.50%)
AMZN   187.40 (-0.87%)
TSLA   172.48 (-1.21%)
NVDA   893.65 (-1.38%)
AMD   163.99 (-3.82%)
NIO   4.14 (-7.17%)
BABA   72.37 (-3.31%)
T   16.43 (+0.06%)
F   12.70 (-2.61%)
MU   123.52 (-3.13%)
GE   155.08 (-1.47%)
CGC   8.01 (-1.72%)
DIS   114.51 (-2.25%)
AMC   2.71 (-3.21%)
PFE   26.19 (-0.57%)
PYPL   65.25 (-0.84%)
XOM   122.28 (+0.40%)
NASDAQ:NAMS

NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis

$19.62
-0.31 (-1.56%)
(As of 11:42 AM ET)
Today's Range
$19.51
$20.04
50-Day Range
$18.95
$24.23
52-Week Range
$5.63
$26.35
Volume
17,717 shs
Average Volume
234,669 shs
Market Capitalization
$1.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.25

NewAmsterdam Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
66.8% Upside
$33.25 Price Target
Short Interest
Healthy
0.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of NewAmsterdam Pharma in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$4.10 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.89) to ($1.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.03 out of 5 stars

Medical Sector

1045th out of 2,784 stocks

Pharmaceutical Preparations Industry

463rd out of 1,302 stocks

NAMS stock logo

About NewAmsterdam Pharma Stock (NASDAQ:NAMS)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NAMS Stock Price History

NAMS Stock News Headlines

Options trading has suddenly become more reliable.
When it hits at a stunning 96% win rate... Options trading has suddenly become more reliable.
Options trading has suddenly become more reliable.
When it hits at a stunning 96% win rate... Options trading has suddenly become more reliable.
NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma prices $175M share offering
See More Headlines
Receive NAMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/12/2024
Next Earnings (Estimated)
5/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:NAMS
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.25
High Stock Price Target
$37.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+66.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$14.09 million
Book Value
$3.50 per share

Miscellaneous

Free Float
87,035,000
Market Cap
$1.78 billion
Optionable
Not Optionable
Beta
0.02
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Michael Harvey Davidson FACC (Age 68)
    Facp., M.D., CEO, President, Executive Board Member & Director
    Comp: $882k
  • Dr. Johannes Jacob Pieter Kastelein FESC (Age 70)
    M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director
    Comp: $677.76k
  • Mr. Mayur Amrat Somaiya (Age 51)
    Chief Financial Officer
    Comp: $130.58k
  • Mr. Douglas F. Kling (Age 51)
    Chief Operating Officer
  • Mr. Jim Jacobson
    Chief Legal Officer & Secretary
  • Dr. Marc Ditmarsch M.D. (Age 57)
    Chief Development Officer
  • Dr. Sheng Cui Ph.D.
    VP & Head of Chemistry Manufacturing and Controls (CMC)
  • Ms. Annie Neild
    VP & Head of Regulatory Affairs
  • Mr. William Jones Jr. (Age 60)
    M.B.A., Chief Commercial Officer

NAMS Stock Analysis - Frequently Asked Questions

Should I buy or sell NewAmsterdam Pharma stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewAmsterdam Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NAMS shares.
View NAMS analyst ratings
or view top-rated stocks.

What is NewAmsterdam Pharma's stock price target for 2024?

5 Wall Street research analysts have issued twelve-month target prices for NewAmsterdam Pharma's stock. Their NAMS share price targets range from $30.00 to $37.00. On average, they anticipate the company's stock price to reach $33.25 in the next year. This suggests a possible upside of 66.8% from the stock's current price.
View analysts price targets for NAMS
or view top-rated stocks among Wall Street analysts.

How have NAMS shares performed in 2024?

NewAmsterdam Pharma's stock was trading at $11.17 at the beginning of 2024. Since then, NAMS shares have increased by 78.4% and is now trading at $19.93.
View the best growth stocks for 2024 here
.

When is NewAmsterdam Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our NAMS earnings forecast
.

Who are NewAmsterdam Pharma's major shareholders?

NewAmsterdam Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Yarbrough Capital LLC (0.03%). Insiders that own company stock include James N Topper, Johannes Jacob Piete Kastelein and Louis G Lange.
View institutional ownership trends
.

How do I buy shares of NewAmsterdam Pharma?

Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NAMS) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners